Cabaletta Bio stockholders approve doubling authorized common shares to 300M, elect directors at annual meeting

Cabaletta Bio, Inc.

Authorized shares increased from 150M to 300M; approved by 32.6M for vs 2.0M against.
Steven Nichtberger, M.D. and Mark Simon, MBA re-elected as Class III directors through 2028.
Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2025.
Say-on-pay approved with 52% support; stockholders selected annual frequency for future advisory votes.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.